Iovance Biotherapeutics(IOVA) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results Quarterly Revenue Growth of 13% to ~$68 Million Gross Margin Increased to 43% on Improved Execution and Operational Ef iciency Best-in-Class Clinical Profile for Lifileucel in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) with Median Duration of Response Not Reached after 25+ Months Follow Up Opportunity to Address up to 30,000 Patients Globally with Previously Treated ...